China Human Vaccine Industry Report, 2015-2018
  • Mar.2015
  • Hard Copy
  • USD $2,650
  • Pages:138
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM063
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,850

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies’ (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China’s human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.

However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume. Moreover, private and foreign brands hold a dominant position in the markets of Haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, and influenza vaccine, together making up 91.9%, 83.6%, 86.5%, and 69.5% in terms of lot release volume in 2014.

人用疫苗 英文_副本.png?

Being bullish about China’s demand for human vaccines and exports, many vaccine producers scale up efforts in vaccine R&D or expand capacity, such as Walvax Biotechnology. By early 2015, GMP on-site certification had been carried out for the company’s Diphtheria-tetanus-acellular pertussis combined vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and DTaP/Hib had made their way into clinical trials; the company is applying registration for meningococcal polysaccharide vaccine (Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru, Thailand, and India.

China Human Vaccine Industry Report, 2015-2018 highlights the following:
20120114.gifOperating environment, overall situation, sales channel, etc. of China human vaccine industry;
20120114.gifSupply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
20120114.gifSupply & demand, competitive landscape, and market prices of 10 product segments (including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine) in China;
20120114.gifOperation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

1 Overview of Vaccine Industry
1.1 Definition and Classification 
1.2 Industry Chain

2 Overview of China Human Vaccine Industry & Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.3 Status Quo
2.4 Supply & Demand
2.5 Competitive Landscape
2.6 Developments
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competitive Landscape
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply & Demand
3.2.2 Competitive Landscape
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competitive Landscape
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competitive Landscape
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competitive Landscape
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine 
3.6.1 Supply & Demand
3.6.2 Competitive Landscape
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competitive Landscape
3.7.3 Market Price
3.8 Pneumococca Vaccine
3.8.1 Supply & Demand
3.8.2 Competitive Landscape
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply & Demand
3.9.2 Competitive Landscape
3.9.3 Market Development & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competitive Landscape

4 China’s Import and Export of Vaccines 
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Destinations
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Sources of Imported Vaccines

5 Major Chinese Vaccine Producers
5.1 China National Biotec Group Co., Ltd.
5.1.1 Beijing Tiantan Biological Products Co., Ltd.
5.1.2 Chengdu Institute of Biological Products Co., Ltd.
5.1.3 Shanghai Institute of Biological Products Co., Ltd. 
5.1.4 Wuhan Institute of Biological Products Co., Ltd. 
5.1.5 Lanzhou Institute of Biological Products Co., Ltd. 
5.1.6 Changchun Institute of Biological Products Co., Ltd. 
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Customers and Suppliers
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.2.8 Development Prospect and Forecast
5.3 Chongqing Zhifei Biological Products Co., Ltd. 
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Major Customers
5.3.6 R&D and Investment
5.3.7 Development Prospect and Forecast
5.4 Walvax Biotechnology Co., Ltd. 
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Customers and Suppliers
5.4.6 R&D and Investment
5.4.7 Development Prospect and Forecast
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Major Customers
5.6.6 Liaoning Chengda Biotechnology Co., Ltd
5.6.7 Development Prospect and Forecast
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 NCPC GeneTech Biotechnology Development Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.13 Dalian Aleph Biomedical Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Beijing Minhai Biotechnology Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.15 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
5.15.1 Profile
5.15.2 Operation
5.16 Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.
Classification of Vaccines
Vaccine Industry Chain
Global Human Vaccine Market Size, 2008-2014
Revenue of Global Top5 Human Vaccine Producers, 2008-2014
Main Mergers & Acquisitions in Vaccine Industry Worldwide, 2005-2014
Policies on Vaccine Industry in China
Revenue and Total Profit of Bio-pharmaceutical Industry in China, 2007-2014
Chinese Human Vaccine Market Size, 2007-2014
Main Human Vaccine Varieties and Producers in China
Gross Margin of Vaccine Business of Major Vaccine Companies in China, 2007-2014
Lot Release Volume of EPI Vaccines and Extra EPI Vaccines, 2007-2014
China’s EPI Human Vaccine Market Shares by Lot Release Volume, 2008-2014
China’s Extra EPI Human Vaccine Market Shares by Lot Release Volume, 2008-2014
Vaccine Business Revenue of Major Vaccine Companies in China, 2011-2014
Human Vaccines under Review of CFDA, 2014
Events Related to Vaccine Business of Foreign Companies in China, 2011-2014
Diagram of Vaccine Distribution Channel in China
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2014
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2014
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2014
Market Price of Hepatitis B Vaccine in Some Parts of China, 2014
Epidemic Meningitis Morbidity and Mortality in China, 2008-2013
Meningococcal Vaccine Lot Release Volume in China by Type, 2007-2014
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2007-2014 (Million Doses)
Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2009-2014(Million Bottles) 
Suppliers and Lot Release Volume of A+C Meningococcal Vaccine, 2007-2014
Suppliers and Lot Release Volume of ACYW135 Meningococcal Vaccine in China, 2008-2014
Market Prices of Meningococcal Vaccine in Some Parts of China, 2014 
Hepatitis A Morbidity and Mortality in China, 2008-2013
Hepatitis A Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of Hepatitis A Vaccine in China, 2007-2014
Market Prices of Hepatitis A Vaccine in Some Parts of China, 2014 
China’s Demand for Hepatitis A Vaccine, 2014-2018E
Influenza Morbidity and Mortality in China, 2008-2013
H1N1 Influenza Morbidity and Mortality in China, 2009-2012
Influenza Vaccine Lot Release Volume in China by Type, 2007-2014
Suppliers and Lot Release Volume of Influenza Split Vaccine in China, 2007-2014
Suppliers and Lot Release Volume of Subunit Influenza Vaccine in China, 2007-2012
Market Prices of Influenza Vaccine in Some Parts of China, 2014
Hib Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of Hib Vaccine in China, 2007-2014
Market Prices of Hib Vaccine in Some Parts of China, 2014
Sales Volume of Hib Vaccine in China, 2014-2018E
Rabies Morbidity and Mortality in China, 2007-2013
Human Rabies Vaccine Lot Release Volume in China, 2007-2014
Human Rabies Vaccine Lot Release Volume in China by Type, 2007-2014
Suppliers and Lot Release Volume of Human (Vero Cell) Rabies Vaccine in China, 2007-2014
Suppliers and Lot Release Volume of Human (BHK Cell) Rabies Vaccine in China, 2007-2014
Market Prices of Human Rabies Vaccine in Some Provinces of China, 2014
China’s Demand for Human Rabies Vaccine in China, 2013-2018E
Varicella Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of Varicella Vaccine in China, 2007-2014
Market Price of Varicella Vaccine in Some Parts of China, 2014
Pneumococcal Vaccine Lot Release Volume in China, 2007-2014
Suppliers and Lot Release Volume of 7-valent and 23-valent Pneumococcal Vaccines in China, 2007-2014
Market Prices of Pneumococcal Vaccine in Some Parts of China, 2014
DPT Vaccine Lot Release Volume in China, 2007-2014
Acellular PDT Vaccine Lot Release Volume in China, 2007-2014
Poliomyelitis Vaccine Lot Release Volume in China, 2007-2014
Poliomyelitis Vaccine Suppliers and Lot Release Volume in China, 2007-2014
Export Volume and Value of Human Vaccines in China, 2009-2014
Average Export Prices of Human Vaccines in China, 2009-2014
Destinations of Exported Human Vaccines from China, 2014
Import Volume and Value of Human Vaccines in China, 2009-2014
Average Import Prices of Human Vaccines in China, 2009-2014
Sources of Imported Human Vaccines in China, 2014
Subsidiaries and Their Revenue and Profit of Beijing Tiantan Biological Products, 2014
Revenue and Operating Income of Beijing Tiantan Biological Products, 2007-2014
Revenue Breakdown of Beijing Tiantan Biological Products by Sector, 2007-2014
Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2007-2014
Beijing Tiantan Biological Products’ Procurement from Top5 Suppliers and % of Total Procurement, 2007-2014
Beijing Tiantan Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2007-2014
Gross Margin of Beijing Tiantan Biological Products by Sector, 2007-2014
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2009-2014
Vaccine Revenue of Beijing Tiantan Biological Products, 2007-2014
Vaccine Lot Release Volume Breakdown of Beijing Tiantan Biological Products by Product, 2009-2014
Revenue and Operating Income of Beijing Tiantan Biological Products, 2014-2018E
Vaccine Varieties of Chengdu Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2009-2014
Vaccine Varieties of Shanghai Institute of Biological Products
Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2009-2014
Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2009-2014
Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2009-2014
Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2009-2014
Revenue and Operating Income of Hualan Biological Engineering, 2007-2014
Revenue Breakdown of Hualan Biological Engineering by Sector, 2007-2014
Gross Margin of Hualan Biological Engineering by Product, 2007-2014
Hualan Biological Engineering’s Revenue from Top5 Customers and % of Total Revenue, 2007-2014
Hualan Biological Engineering’s Procurement from Top5 Suppliers and % of Total Procurement, 2007-2014
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2007-2014
Lot Release Volume Breakdown of Hualan Biological Engineering by Product, 2011-2014
Vaccine Revenue and Gross Margin of Hualan Biological Engineering, 2008-2014
Revenue and Operating Income of Hualan Biological Engineering, 2014-2018E
Subsidiaries and Main Products of Chongqing Zhifei Biological Products
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2008-2014
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2014
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2014
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2009-2014
Gross Margin of Chongqing Zhifei Biological Products, 2009-2014
Gross Margins of Chongqing Zhifei Biological Products’ Home-grown Vaccines, 2008-2014
Gross Margins of Chongqing Zhifei Biological Products’ Agent Vaccines, 2008-2014
Chongqing Zhifei Biological Products’ Revenue from Top5 Customers and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2008-2014
Progress of the Products under Research of Chongqing Zhifei Biological Products by the end of 2014
Revenue and Operating Income of Chongqing Zhifei Biological Products, 2014-2018E
Industrial Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2014
Vaccines on the Market and Capacities of Walvax Biotechnology
Revenue Breakdown of Walvax Biotechnology by Product, 2009-2014
Lot Release Volume Breakdown of Walvax Biotechnology by Product, 2009-2014
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2014
Gross Margin of Walvax Biotechnology by Product, 2007-2014
Walvax Biotechnology’s Revenue from Top5 Customers and % of Total Revenue, 2008-2014
Walvax Biotechnology’s Procurement from Top5 Suppliers and % of Total Procurement, 2008-2014
Progress of Projects under Construction of Walvax Biotechnology by the end of 2014
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2014
Progress of the Products under Research of Walvax Biotechnology by the end of 2014
Revenue and Operating Income of Walvax Biotechnology, 2014-2018E
Revenue and Operating Income of Sinovac Biotech, 2008-2014
Revenue Breakdown of Sinovac Biotech by Product, 2008-2014
Vaccine Lot Release Volume Breakdown of Sinovac Biotech by Product, 2009-2014
R&D Costs and % of Total Revenue of Sinovac Biotech, 2008-2013
Revenue and Operating Income of Liaoning Chengda, 2008-2014
Revenue Breakdown of Liaoning Chengda by Sector, 2008-2013
Revenue Breakdown of Liaoning Chengda by Region, 2008-2014
Gross Margin of Liaoning Chengda by Sector, 2008-2014
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2008-2014
Name List and Revenue Contribution of Liaoning Chengda’s Top 5 Customers, 2013
Human Vaccine Lot Release Volume of Liaoning Chengda Biotechnology, 2009-2014
Revenue and Net Income of Liaoning Chengda Biotechnology, 2012-2014
Revenue Structure of Liaoning Chengda Biotechnology by Product, 2012-2014
Name List and Revenue Contribution of Liaoning Chengda Biotechnology’s Top5 Customers, 2013-2014
Name List and Procurement Share of Liaoning Chengda Biotechnology’s Top5 Suppliers, 2013-2014
Revenue and Operating Income of Liaoning Chengda, 2014-2018E
Revenue and Operating Income of Changchun BCHT Biotechnology, 2009-2014
Vaccine Lot Release Volume Breakdown of Changchun BCHT Biotechnology by Product, 2009-2014
Lot Release Volume Breakdown of Changchun Changsheng Life Sciences by Product, 2008-2014
Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical
Vaccine Lot Release Volume Breakdown of Zhejiang Tianyuan Bio-Pharmaceutical by Product, 2009-2014
Revenue and Operating Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
Assets and Liabilities of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
Hepatitis B Vaccine Lot Release Volume Breakdown of Shenzhen Kangtai Biological Products by Dosage Form, 2007-2014
Vaccine Lot Release Volume Breakdown of Dalian Hissen Bio-pharm by Product, 2009-2014
Vaccines under Research of Dalian Hissen Bio-pharm, 2014
Vaccine Lot Release Volume of NCPC GeneTech Biotechnology Development, 2009-2014
Lot Release Volume of Dalian Aleph Biomedical, 2009-2014
Revenue and Operating Income of Dalian Aleph Biomedical, 2013-2014
Assets and Liabilities of Dalian Aleph Biomedical, 2013-2014
Vaccines under Research of Beijing Minhai Biotechnology
Vaccine Lot Release Volume Breakdown of Beijing Minhai Biotechnology by Product, 2009-2014
Revenue and Operating Income of Beijing Minhai Biotechnology, 2013-2014
Assets and Liabilities of Beijing Minhai Biotechnology, 2013-2014
Vaccine Lot Release Volume Breakdown of Shenzhen Sanofi Pasteur Biological Products by Product, 2009-2014
Revenue and Operating Income of Shenzhen Sanofi Pasteur Biological Products, 2013-2014
Assets and Liabilities of Shenzhen Sanofi Pasteur Biological Products, 2013-2014

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号